PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.03%
Positive revenue growth while TSM is negative. John Neff might see a notable competitive edge here.
191.95%
Positive gross profit growth while TSM is negative. John Neff would see a clear operational edge over the competitor.
159.23%
Positive EBIT growth while TSM is negative. John Neff might see a substantial edge in operational management.
159.23%
Positive operating income growth while TSM is negative. John Neff might view this as a competitive edge in operations.
160.20%
Positive net income growth while TSM is negative. John Neff might see a big relative performance advantage.
161.29%
Positive EPS growth while TSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
161.29%
Positive diluted EPS growth while TSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.80%
Share count expansion well above TSM's 0.00%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.73%
Diluted share count expanding well above TSM's 0.00%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
517.80%
Positive OCF growth while TSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
5868.30%
FCF growth above 1.5x TSM's 1153.50%. David Dodd would verify if the firm’s strategic investments yield superior returns.
191.98%
10Y revenue/share CAGR at 75-90% of TSM's 254.93%. Bill Ackman would press for new markets or product lines to narrow the gap.
27.81%
5Y revenue/share CAGR at 75-90% of TSM's 34.60%. Bill Ackman would encourage strategies to match competitor’s pace.
-27.28%
Negative 3Y CAGR while TSM stands at 15.80%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
722.75%
OCF/share CAGR of 722.75% while TSM is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
122.93%
5Y OCF/share CAGR above 1.5x TSM's 10.98%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-46.34%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
107.29%
Below 50% of TSM's 780.59%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
14.91%
Positive 5Y CAGR while TSM is negative. John Neff might view this as a strong mid-term relative advantage.
-65.38%
Negative 3Y CAGR while TSM is 0.53%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
449.65%
Equity/share CAGR of 449.65% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
89.75%
5Y equity/share CAGR above 1.5x TSM's 28.05%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
12.42%
Below 50% of TSM's 31.00%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.90%
Our AR growth while TSM is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-12.99%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
4.94%
Positive asset growth while TSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
4.15%
50-75% of TSM's 5.76%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-1.58%
We’re deleveraging while TSM stands at 52.96%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-2.90%
Our R&D shrinks while TSM invests at 1.49%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.29%
We cut SG&A while TSM invests at 1.26%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.